Prognostic significance of the sodium channel blocker test in patients with Brugada syndrome

Akira Ueoka, Hiroshi Morita, Atsuyuki Watanabe, Yoshimasa Morimoto, Satoshi Kawada, Motomi Tachibana, Masakazu Miyamoto, Koji Nakagawa, Nobuhiro Nishii, Hiroshi Itoh

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background--A drug provocation test using a sodium channel blocker (SCB) can unmask a type 1 ECG pattern in patients with Brugada syndrome. However, the prognostic value of the results of an SCB challenge is limited in patients with non-type 1 ECG. We investigated the associations of future risk for ventricular fibrillation with SCB-induced ECG changes and ventricular tachyarrhythmias (VTAs). Methods and Results--We administered intravenous pilsicainide to 245 consecutive patients with Brugada syndrome (181 patients with spontaneous type 1 ECG, 64 patients with non-type 1 ECG). ECG parameters before and after the test and occurrence of drug-induced VTAs were evaluated. During a mean follow-up period of 113±57 months, fatal VTA events occurred in 31 patients (sudden death: n=3, ventricular tachycardia/ventricular fibrillation: n=28). Symptomatic patients and spontaneous type 1 ECG were associated with future fatal arrhythmic events. Univariable analysis of ECG parameters after the test showed that long PQ and QRS intervals, high ST level, and SCB-induced VTAs were associated with later VTA events during follow-up. Multivariable analysis showed that symptomatic patients, high ST level (V1) ≥0.3 mV after the test, and SCB-induced VTAs were independent predictors for future fatal arrhythmic events (hazard ratios: 3.28, 2.80, and 3.62, 95% confidence intervals: 1.54-7.47, 1.32-6.35, and 1.64-7.75, respectively; P < 0.05). Conclusions--SCB-induced VTAs and ST-segment augmentation are associated with an increased risk of the development of ventricular tachycardia/ventricular fibrillation events during follow-up in patients with Brugada syndrome.

Original languageEnglish
Article numbere008617
JournalJournal of the American Heart Association
Volume7
Issue number10
DOIs
Publication statusPublished - May 15 2018

Fingerprint

Sodium Channel Blockers
Brugada Syndrome
Tachycardia
Electrocardiography
Ventricular Fibrillation
Ventricular Tachycardia
Sudden Death
Pharmaceutical Preparations
Confidence Intervals

Keywords

  • Brugada syndrome
  • Risk stratification
  • Sodium channel blocker
  • Ventricular fibrillation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Prognostic significance of the sodium channel blocker test in patients with Brugada syndrome. / Ueoka, Akira; Morita, Hiroshi; Watanabe, Atsuyuki; Morimoto, Yoshimasa; Kawada, Satoshi; Tachibana, Motomi; Miyamoto, Masakazu; Nakagawa, Koji; Nishii, Nobuhiro; Itoh, Hiroshi.

In: Journal of the American Heart Association, Vol. 7, No. 10, e008617, 15.05.2018.

Research output: Contribution to journalArticle

@article{c112b471d37e45969270176e81ee926a,
title = "Prognostic significance of the sodium channel blocker test in patients with Brugada syndrome",
abstract = "Background--A drug provocation test using a sodium channel blocker (SCB) can unmask a type 1 ECG pattern in patients with Brugada syndrome. However, the prognostic value of the results of an SCB challenge is limited in patients with non-type 1 ECG. We investigated the associations of future risk for ventricular fibrillation with SCB-induced ECG changes and ventricular tachyarrhythmias (VTAs). Methods and Results--We administered intravenous pilsicainide to 245 consecutive patients with Brugada syndrome (181 patients with spontaneous type 1 ECG, 64 patients with non-type 1 ECG). ECG parameters before and after the test and occurrence of drug-induced VTAs were evaluated. During a mean follow-up period of 113±57 months, fatal VTA events occurred in 31 patients (sudden death: n=3, ventricular tachycardia/ventricular fibrillation: n=28). Symptomatic patients and spontaneous type 1 ECG were associated with future fatal arrhythmic events. Univariable analysis of ECG parameters after the test showed that long PQ and QRS intervals, high ST level, and SCB-induced VTAs were associated with later VTA events during follow-up. Multivariable analysis showed that symptomatic patients, high ST level (V1) ≥0.3 mV after the test, and SCB-induced VTAs were independent predictors for future fatal arrhythmic events (hazard ratios: 3.28, 2.80, and 3.62, 95{\%} confidence intervals: 1.54-7.47, 1.32-6.35, and 1.64-7.75, respectively; P < 0.05). Conclusions--SCB-induced VTAs and ST-segment augmentation are associated with an increased risk of the development of ventricular tachycardia/ventricular fibrillation events during follow-up in patients with Brugada syndrome.",
keywords = "Brugada syndrome, Risk stratification, Sodium channel blocker, Ventricular fibrillation",
author = "Akira Ueoka and Hiroshi Morita and Atsuyuki Watanabe and Yoshimasa Morimoto and Satoshi Kawada and Motomi Tachibana and Masakazu Miyamoto and Koji Nakagawa and Nobuhiro Nishii and Hiroshi Itoh",
year = "2018",
month = "5",
day = "15",
doi = "10.1161/JAHA.118.008617",
language = "English",
volume = "7",
journal = "Journal of the American Heart Association",
issn = "2047-9980",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Prognostic significance of the sodium channel blocker test in patients with Brugada syndrome

AU - Ueoka, Akira

AU - Morita, Hiroshi

AU - Watanabe, Atsuyuki

AU - Morimoto, Yoshimasa

AU - Kawada, Satoshi

AU - Tachibana, Motomi

AU - Miyamoto, Masakazu

AU - Nakagawa, Koji

AU - Nishii, Nobuhiro

AU - Itoh, Hiroshi

PY - 2018/5/15

Y1 - 2018/5/15

N2 - Background--A drug provocation test using a sodium channel blocker (SCB) can unmask a type 1 ECG pattern in patients with Brugada syndrome. However, the prognostic value of the results of an SCB challenge is limited in patients with non-type 1 ECG. We investigated the associations of future risk for ventricular fibrillation with SCB-induced ECG changes and ventricular tachyarrhythmias (VTAs). Methods and Results--We administered intravenous pilsicainide to 245 consecutive patients with Brugada syndrome (181 patients with spontaneous type 1 ECG, 64 patients with non-type 1 ECG). ECG parameters before and after the test and occurrence of drug-induced VTAs were evaluated. During a mean follow-up period of 113±57 months, fatal VTA events occurred in 31 patients (sudden death: n=3, ventricular tachycardia/ventricular fibrillation: n=28). Symptomatic patients and spontaneous type 1 ECG were associated with future fatal arrhythmic events. Univariable analysis of ECG parameters after the test showed that long PQ and QRS intervals, high ST level, and SCB-induced VTAs were associated with later VTA events during follow-up. Multivariable analysis showed that symptomatic patients, high ST level (V1) ≥0.3 mV after the test, and SCB-induced VTAs were independent predictors for future fatal arrhythmic events (hazard ratios: 3.28, 2.80, and 3.62, 95% confidence intervals: 1.54-7.47, 1.32-6.35, and 1.64-7.75, respectively; P < 0.05). Conclusions--SCB-induced VTAs and ST-segment augmentation are associated with an increased risk of the development of ventricular tachycardia/ventricular fibrillation events during follow-up in patients with Brugada syndrome.

AB - Background--A drug provocation test using a sodium channel blocker (SCB) can unmask a type 1 ECG pattern in patients with Brugada syndrome. However, the prognostic value of the results of an SCB challenge is limited in patients with non-type 1 ECG. We investigated the associations of future risk for ventricular fibrillation with SCB-induced ECG changes and ventricular tachyarrhythmias (VTAs). Methods and Results--We administered intravenous pilsicainide to 245 consecutive patients with Brugada syndrome (181 patients with spontaneous type 1 ECG, 64 patients with non-type 1 ECG). ECG parameters before and after the test and occurrence of drug-induced VTAs were evaluated. During a mean follow-up period of 113±57 months, fatal VTA events occurred in 31 patients (sudden death: n=3, ventricular tachycardia/ventricular fibrillation: n=28). Symptomatic patients and spontaneous type 1 ECG were associated with future fatal arrhythmic events. Univariable analysis of ECG parameters after the test showed that long PQ and QRS intervals, high ST level, and SCB-induced VTAs were associated with later VTA events during follow-up. Multivariable analysis showed that symptomatic patients, high ST level (V1) ≥0.3 mV after the test, and SCB-induced VTAs were independent predictors for future fatal arrhythmic events (hazard ratios: 3.28, 2.80, and 3.62, 95% confidence intervals: 1.54-7.47, 1.32-6.35, and 1.64-7.75, respectively; P < 0.05). Conclusions--SCB-induced VTAs and ST-segment augmentation are associated with an increased risk of the development of ventricular tachycardia/ventricular fibrillation events during follow-up in patients with Brugada syndrome.

KW - Brugada syndrome

KW - Risk stratification

KW - Sodium channel blocker

KW - Ventricular fibrillation

UR - http://www.scopus.com/inward/record.url?scp=85046950671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046950671&partnerID=8YFLogxK

U2 - 10.1161/JAHA.118.008617

DO - 10.1161/JAHA.118.008617

M3 - Article

C2 - 29748178

AN - SCOPUS:85046950671

VL - 7

JO - Journal of the American Heart Association

JF - Journal of the American Heart Association

SN - 2047-9980

IS - 10

M1 - e008617

ER -